GlassScriptPhysician profile
Gabor Varadi
NPI 1780894352
$1,852.95
in general payments reported to CMS, 2019-2025
25 companies · $454 in 2025
The $454 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $21.11 · 2021: $11.92 · 2022: $14.53 · 2023: $422 · 2024: $705 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.84 |
| Education | $172.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $260.75 | 2023-2025 | Pyrukynd |
| Janssen Biotech, INC. | $233.18 | 2020-2024 | Darzalex, Tecvayli, Erleada |
| Eisai INC. | $213.95 | 2019-2024 | |
| Pfizer INC. | $155.66 | 2019-2024 | |
| Sobi, INC | $142.69 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $116.75 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $116.14 | 2025 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $82.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $70.70 | 2023-2025 | Imfinzi, Calquence |
| Glaxosmithkline, LLC. | $62.91 | 2024-2025 | Blenrep, Ojjaara, Jemperli |
| Astellas Pharma US INC | $47.34 | 2023-2025 | Vyloy, Xospata |
| Celgene Corporation | $45.05 | 2023-2024 | Reblozyl |
| Genzyme Corporation | $36.62 | 2025 | |
| Gilead Sciences, INC. | $35.89 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $34.82 | 2024 | Libtayo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31.91 | 2023 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $27.61 | 2024 | Ninlaro |
| Amgen INC. | $23.88 | 2023 | Xgeva, Vectibix, Nplate |
| Merck Sharp & Dohme LLC | $20.52 | 2023 | Keytruda, Lynparza |
| Deciphera Pharmaceuticals INC. | $17.64 | 2025 | Romvimza, Qinlock |
| Aveo Pharmaceuticals, INC. | $17.40 | 2024 | |
| Apellis Pharmaceuticals, INC. | $15.91 | 2024 | Empaveli |
| Adaptive Biotechnologies Corporation | $15.56 | 2023 | Clonoseq |
| Karyopharm Therapeutics INC. | $14.53 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabor Varadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.